Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.41 |
| ▸ | PDE4A | P27815 | 10/20 | 0.40 |
| ▸ | PDE4D | Q08499 | 9/20 | 0.40 |
| ▸ | PDE4B | Q07343 | 5/20 | 0.40 |
| ▸ | PDE4C | Q08493 | 5/20 | 0.40 |
| ▸ | PDE5A | O76074 | 2/20 | 0.40 |
| ▸ | QRFPR | Q96P65 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15215721 | 0.90 | PLA2G7 (0.36) | EPHX2QRFPR | |
| SCHEMBL1157461 | 0.81 | POLB (0.54) | POLBEPHX2PDE4APDE4DPDE4B | |
| SCHEMBL4202484 | 0.80 | POLB (0.48) | POLBPDE4APDE4DPDE4BPDE4C | |
| SCHEMBL1157366 | 0.77 | POLB (0.56) | POLBPDE4APDE4DPDE4BPDE4C | |
| SCHEMBL1157857 | 0.75 | POLB (0.54) | POLBEPHX2PDE4APDE4DPDE4B | |
| SCHEMBL1157875 | 0.74 | PDE4D (0.64) | POLBPDE4APDE4DPDE4BPDE4C | |
| SCHEMBL1157396 | 0.74 | POLB (0.53) | POLBPDE4APDE4DPDE4BPDE4C | |
| SCHEMBL1157431 | 0.73 | POLB (0.55) | POLBPDE4APDE4DPDE4BPDE4C | |
| SCHEMBL1157747 | 0.73 | QRFPR (0.61) | POLBPDE4APDE4DPDE4BPDE4C | |
| SCHEMBL1157580 | 0.73 | POLB (0.54) | POLBPDE4APDE4DPDE4BPDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170298058-A1 | HETEROCYCLIC RING AND CARBOCYCLIC DERIVATIVE | SHIONOGI & CO (JP) | 2017-10-19 | — | — | US | disclosed |
| EP-2604260-B1 | NOVEL HETEROCYCLIC DERIVATIVES AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | SHIONOGI & CO (JP) | 2017-05-10 | — | — | EP | disclosed |
| US-9550763-B2 | Heterocyclic ring and carbocyclic derivative | SHIONOGI & CO., LTD. (JP) | 2017-01-24 | — | — | US | disclosed |
| US-20160024072-A1 | Heterocyclic Ring and Carbocyclic Derivative | SHIONOGI & CO., LTD. (JP) | 2016-01-28 | — | — | US | disclosed |
| US-9212130-B2 | Heterocyclic derivative and pharmaceutical composition comprising the same | SHIONOGI & CO., LTD. (JP) | 2015-12-15 | — | — | US | disclosed |
| WO-2013118855-A1 | HETEROCYCLIC RING AND CARBOCYCLIC DERIVATIVE | 塩野義製薬株式会社 (JP) | 2013-08-15 | — | — | WO | disclosed |
| EP-2604260-A1 | NOVEL HETEROCYCLIC DERIVATIVES AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | Shionogi&Co., Ltd. (JP) | 2013-06-19 | — | — | EP | disclosed |
| WO-2012020742-A1 | NOVEL HETEROCYCLIC DERIVATIVES AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | 塩野義製薬株式会社 (JP) | 2012-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170298058-A1 | HETEROCYCLIC RING AND CARBOCYCLIC DERIVATIVE | P2RX3, P2RX7, P2RX2 | POLB 4279/4885EPHX2 556/4885PDE4A 2249/4885 |
| US-20160024072-A1 | Heterocyclic Ring and Carbocyclic Derivative | P2RX3, P2RX7, P2RX2 | POLB 4279/4885EPHX2 556/4885PDE4A 2249/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.